[ad_1]
At the Szeged University (SZTE) clinic, coronavirus patients can be treated for the first time in the country with the drug favipiravir Avigan, which is expected to have a shorter recovery time and fewer complications during the illness, said the Friday to MTI the press department of the university.
In communication Csaba LengyelQuoting the president of the Albert Szent-Györgyi Clinical Center at the University of Szeged, it was written that the university was the first in the country to initiate research into treating coronavirus patients with the drug Avigan. Based on available preliminary clinical data, a clinical trial of the broad-spectrum Japanese antiviral drug favipiravir was started in the HECRIN consortium, they added.
The consortium member is the SZTE Clinical Trials Coordination Office, which was involved in the preparation of the trials in Hungary. Thanks to this, the University of Szeged also received the most promising drug, which was previously donated by the Japanese government to 44 countries, including Hungary.
According to a clinical study conducted in Japan in the past six months, the drug prevented the virus from multiplying in patients with moderate coronavirus who had been treated for incipient pneumonia and alleviated clinical symptoms such as fever or shortness of breath within 12 days. It has also successfully prevented the deterioration of patients, making intensive therapeutic treatment for many of them avoidable.
The drug should only be administered to critically ill patients in a hospital based on testing criteria and at the discretion of examining physicians. At the same time, development of a drug containing favipiravir is underway in Hungary, so experts hope that clinical testing of it will start soon – read the announcement.
[ad_2]
